Amarin Corporation Plc (AMRN) 1.13 $AMRN
Good News: Vascepa Kept Its Place On National Formularies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 17, 1:33PM CST
AMRN: 1.13 (+0.15)
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris
PR Newswire - Wed Dec 17, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
IMMU: 4.78 (-0.02), NVAX: 5.76 (-0.17), AMRN: 1.13 (+0.15), AEZS: 0.60 (unch), CELG: 113.52 (+1.66), CELGZ: 3.15 (unch)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 39.72 (+0.01), ZSPH: 45.12 (+3.55), AMRN: 1.13 (+0.15), OPHT: 45.60 (+0.73), AERI: 31.25 (+2.06), ASPX: 53.11 (+0.63), CNCE: 13.95 (+0.63), ICEL: 6.40 (-0.03), GWPH: 70.04 (+2.36), AUXL: 34.47 (+0.09), RTRX: 12.67 (+0.43), RCPT: 124.81 (+2.30), AAVL: 58.92 (+4.92), AKBA: 11.50 (-0.14), EXPR: 14.61 (-0.08), RARE: 46.40 (+2.52), RLYP: 30.80 (unch), PETX: 18.21 (+0.39), ENTA: 50.45 (-0.40), RDUS: 41.21 (+2.30), CARA: 10.60 (+0.63), FLML: 17.09 (-0.04), ALIM: 5.81 (+0.27), ANIP: 56.99 (+0.60), ICPT: 159.49 (+3.49), RVNC: 16.66 (-0.28), POZN: 7.88 (-0.12), FPRX: 27.71 (+0.71), ZFGN: 30.92 (+0.08), CRIS: 1.48 (-0.02), QLTI: 4.08 (+0.07), PCYC: 124.46 (+2.20), PTX: 9.69 (+0.30), CLDN: 20.17 (+0.64), RIGL: 2.39 (+0.12), HPTX: 24.28 (+0.28), AMPH: 11.84 (+0.23), INO: 9.32 (+0.14), VSAR: 22.33 (-0.12), FMI: 22.18 (-0.04), TBPH: 14.70 (-0.22), XLRN: 38.26 (-0.70), MGNX: 35.18 (+0.11), INSM: 15.96 (+0.49), ONTX: 3.89 (+0.60), ALDR: 28.81 (-0.28), SAGE: 38.70 (+2.10), KITE: 60.61 (+2.94), CGEN: 8.60 (+0.27), FOLD: 8.61 (+0.29), KPTI: 37.99 (+0.56)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 39.72 (+0.01), ZSPH: 45.12 (+3.55), AMRN: 1.13 (+0.15), OPHT: 45.60 (+0.73), AERI: 31.25 (+2.06), ASPX: 53.11 (+0.63), CNCE: 13.95 (+0.63), ICEL: 6.40 (-0.03), GWPH: 70.04 (+2.36), AUXL: 34.47 (+0.09), RTRX: 12.67 (+0.43), RCPT: 124.81 (+2.30), AAVL: 58.92 (+4.92), AKBA: 11.50 (-0.14), EXPR: 14.61 (-0.08), RARE: 46.40 (+2.52), ZGNX: 1.42 (+0.05), RLYP: 30.80 (unch), PETX: 18.21 (+0.39), ENTA: 50.45 (-0.40), RDUS: 41.21 (+2.30), CARA: 10.60 (+0.63), FLML: 17.09 (-0.04), ALIM: 5.81 (+0.27), ANIP: 56.99 (+0.60), ICPT: 159.49 (+3.49), RVNC: 16.66 (-0.28), POZN: 7.88 (-0.12), NDAQ: 47.86 (-0.10), FPRX: 27.71 (+0.71), CRIS: 1.48 (-0.02), ZFGN: 30.92 (+0.08), QLTI: 4.08 (+0.07), PCYC: 124.46 (+2.20), PTX: 9.69 (+0.30), CLDN: 20.17 (+0.64), RIGL: 2.39 (+0.12), HPTX: 24.28 (+0.28), AMPH: 11.84 (+0.23), INO: 9.32 (+0.14), VSAR: 22.33 (-0.12), FMI: 22.18 (-0.04), TBPH: 14.70 (-0.22), XLRN: 38.26 (-0.70), MGNX: 35.18 (+0.11), INSM: 15.96 (+0.49), ONTX: 3.89 (+0.60), ALDR: 28.81 (-0.28), SAGE: 38.70 (+2.10), KITE: 60.61 (+2.94), CGEN: 8.60 (+0.27), FOLD: 8.61 (+0.29), KPTI: 37.99 (+0.56)
Amarin Corporation: Upside Becomes Clearer While The Path To The Finish Line Remains Murky
Outsized Analytics - at Seeking Alpha - Sun Dec 07, 8:47AM CST
AMRN: 1.13 (+0.15), AZN: 70.40 (+0.02), GSK: 42.37 (-0.37)
Amarin to Present at the 25th Annual Oppenheimer Healthcare Conference
Marketwired - Thu Dec 04, 6:02AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 25th Annual Oppenheimer Healthcare Conference in New York City on Thursday, December 11, at 3:20 p.m. ET.
AMRN: 1.13 (+0.15)
Amarin: The Silence Of The Lamb
Scrying Biotech - at Seeking Alpha - Tue Dec 02, 9:08AM CST
AMRN: 1.13 (+0.15)
Why Amarin Corporation PLC Stock Flew 37% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 01, 1:27PM CST
AMRN data by YCharts What: Shares of Amarin , a small-cap biopharmaceutical company focused on developing therapies that are designed to treat cardiovascular diseases, rocketed higher by 37% in November, according to data from S&P...
AMRN: 1.13 (+0.15)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 1.55 (+0.09), AMRN: 1.13 (+0.15), JCP: 6.29 (-0.19), SNSS: 2.75 (+0.20), SWHC: 9.48 (+0.01)
Update: Amarin Earnings Show It Blew Its Chance At 2014 Profitability
The Specialist - at Seeking Alpha - Mon Nov 24, 12:13AM CST
AMRN: 1.13 (+0.15)
Traders Get Bullish on Shares of Amarin, Shares Up 9.7% (AMRN)
Comtex SmarTrend(R) - Fri Nov 21, 12:41PM CST
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 9.7% to $1.36 on 1.1x average daily volume. Amarin has traded 2.3 million shares thus far today, vs. average volume of 2.0 million shares per day. The stock has outperformed the Dow (9.7% to the Dow's 0.3%) and outperformed the S&P 500 (9.7% to the S&P's 0.3%) during today's trading.
AMRN: 1.13 (+0.15)
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:18AM CST
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
ANIP: 56.99 (+0.60), AMRN: 1.13 (+0.15), AMAG: 42.60 (-0.02), AFFX: 9.99 (+0.12)
Amarin Announces Presentation of MARINE and ANCHOR Analyses at the American Heart Association Scientific Sessions Showing Vascepa(R) Significantly Reduced Remnant-Like Particle Cholesterol in Hypertriglyceridemic Patients
Marketwired - Tue Nov 18, 11:17PM CST
Amarin Corporation Plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa® (icosapent ethyl) capsules significantly reduced remnant-like particle cholesterol (RLP-C) levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride (TG) levels ≥ 200 mg/dL and ≥ 500 mg/dL, including patients that received statin therapy. The data were presented today by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago.
AMRN: 1.13 (+0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 11:49AM CST
BOSC: 3.28 (+0.12), ANV: 0.91 (+0.04), BONE: 3.00 (-0.03), TERP: 30.84 (-0.04), BDR: 2.35 (-0.34), AMRN: 1.13 (+0.15), NBS: 3.73 (-0.04), YOKU: 18.31 (+0.50), AMCF: 1.51 (-0.03), GSAT: 2.68 (-0.07), MUX: 1.10 (-0.01), URBN: 35.10 (-0.03), CANF: 3.77 (+0.27), TRT: 2.74 (-0.17), CBSO: 27.51 (+0.58), OME: 10.60 (+0.03), ATLC: 2.60 (+0.24), SUNE: 19.71 (+0.20), FWM: 3.12 (-0.03)
Amarin up again today on Vascepa data
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 10:41AM CST
AMRN: 1.13 (+0.15)
Amarin Up 5.3%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Mon Nov 17, 2:42PM CST
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 5.3% to $1.00 on 1.1x average daily volume. Thus far today, Amarin has traded 1.8 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.3% to the Dow's 0.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.0%) during today's trading.
AMRN: 1.13 (+0.15)
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
at The Street - Fri Nov 14, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OREX: 6.30 (+0.24), AMRN: 1.13 (+0.15), ICPT: 159.49 (+3.49), SPPI: 7.15 (+0.22), MNKD: 5.64 (+0.42)
Rick Harrison of Television's "Pawn Stars(R)" Takes His Patient-Care Message to AHA Scientific Sessions to Raise Awareness of Very High Triglycerides as Part of National Campaign
Marketwired - Thu Nov 13, 6:04AM CST
Making the right deal can meaningfully impact and improve your health when it comes to speaking with your doctor. Rick Harrison, star of the hit television show, "Pawn Stars®," will attend the American Heart Association's (AHA) Scientific Sessions to raise awareness of very high triglycerides (VHTG) (≥ 500 mg/dL), a condition that affects up to four million Americans.(1) Mr. Harrison's AHA visit is sponsored by Amarin Corporation, plc (NASDAQ: AMRN).
AMRN: 1.13 (+0.15)
Update: Amarin's Q3 2014 Earnings Report
Elephant Analytics - at Seeking Alpha - Mon Nov 10, 12:18AM CST
AMRN: 1.13 (+0.15)
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations
Marketwired - Thu Nov 06, 3:04PM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on company operations.
AMRN: 1.13 (+0.15)
Good News: Vascepa Kept Its Place On National Formularies
Clinically Sound Investor - at Seeking Alpha - Wed Dec 17, 1:33PM CST
AMRN: 1.13 (+0.15)
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris
PR Newswire - Wed Dec 17, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Novavax Inc. (NASDAQ: NVAX), Amarin Corporation PLC (NASDAQ: AMRN), Immunomedics Inc. (NASDAQ: IMMU), and Aeterna Zentaris Inc. (NASDAQ: AEZS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 16, 2014, the NASDAQ Composite ended at 4,547.83, down 1.24%, the Dow Jones Industrial Average declined 0.65%, to finish the day at 17,068.87, and the S&P 500 closed at 1,972.74, down 0.85%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 776.88, down 1.27%, while the index has advanced 4.39% in the previous three months. Register for your complimentary reports on these five stocks at:
IMMU: 4.78 (-0.02), NVAX: 5.76 (-0.17), AMRN: 1.13 (+0.15), AEZS: 0.60 (unch), CELG: 113.52 (+1.66), CELGZ: 3.15 (unch)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 39.72 (+0.01), ZSPH: 45.12 (+3.55), AMRN: 1.13 (+0.15), OPHT: 45.60 (+0.73), AERI: 31.25 (+2.06), ASPX: 53.11 (+0.63), CNCE: 13.95 (+0.63), ICEL: 6.40 (-0.03), GWPH: 70.04 (+2.36), AUXL: 34.47 (+0.09), RTRX: 12.67 (+0.43), RCPT: 124.81 (+2.30), AAVL: 58.92 (+4.92), AKBA: 11.50 (-0.14), EXPR: 14.61 (-0.08), RARE: 46.40 (+2.52), RLYP: 30.80 (unch), PETX: 18.21 (+0.39), ENTA: 50.45 (-0.40), RDUS: 41.21 (+2.30), CARA: 10.60 (+0.63), FLML: 17.09 (-0.04), ALIM: 5.81 (+0.27), ANIP: 56.99 (+0.60), ICPT: 159.49 (+3.49), RVNC: 16.66 (-0.28), POZN: 7.88 (-0.12), FPRX: 27.71 (+0.71), ZFGN: 30.92 (+0.08), CRIS: 1.48 (-0.02), QLTI: 4.08 (+0.07), PCYC: 124.46 (+2.20), PTX: 9.69 (+0.30), CLDN: 20.17 (+0.64), RIGL: 2.39 (+0.12), HPTX: 24.28 (+0.28), AMPH: 11.84 (+0.23), INO: 9.32 (+0.14), VSAR: 22.33 (-0.12), FMI: 22.18 (-0.04), TBPH: 14.70 (-0.22), XLRN: 38.26 (-0.70), MGNX: 35.18 (+0.11), INSM: 15.96 (+0.49), ONTX: 3.89 (+0.60), ALDR: 28.81 (-0.28), SAGE: 38.70 (+2.10), KITE: 60.61 (+2.94), CGEN: 8.60 (+0.27), FOLD: 8.61 (+0.29), KPTI: 37.99 (+0.56)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 39.72 (+0.01), ZSPH: 45.12 (+3.55), AMRN: 1.13 (+0.15), OPHT: 45.60 (+0.73), AERI: 31.25 (+2.06), ASPX: 53.11 (+0.63), CNCE: 13.95 (+0.63), ICEL: 6.40 (-0.03), GWPH: 70.04 (+2.36), AUXL: 34.47 (+0.09), RTRX: 12.67 (+0.43), RCPT: 124.81 (+2.30), AAVL: 58.92 (+4.92), AKBA: 11.50 (-0.14), EXPR: 14.61 (-0.08), RARE: 46.40 (+2.52), ZGNX: 1.42 (+0.05), RLYP: 30.80 (unch), PETX: 18.21 (+0.39), ENTA: 50.45 (-0.40), RDUS: 41.21 (+2.30), CARA: 10.60 (+0.63), FLML: 17.09 (-0.04), ALIM: 5.81 (+0.27), ANIP: 56.99 (+0.60), ICPT: 159.49 (+3.49), RVNC: 16.66 (-0.28), POZN: 7.88 (-0.12), NDAQ: 47.86 (-0.10), FPRX: 27.71 (+0.71), CRIS: 1.48 (-0.02), ZFGN: 30.92 (+0.08), QLTI: 4.08 (+0.07), PCYC: 124.46 (+2.20), PTX: 9.69 (+0.30), CLDN: 20.17 (+0.64), RIGL: 2.39 (+0.12), HPTX: 24.28 (+0.28), AMPH: 11.84 (+0.23), INO: 9.32 (+0.14), VSAR: 22.33 (-0.12), FMI: 22.18 (-0.04), TBPH: 14.70 (-0.22), XLRN: 38.26 (-0.70), MGNX: 35.18 (+0.11), INSM: 15.96 (+0.49), ONTX: 3.89 (+0.60), ALDR: 28.81 (-0.28), SAGE: 38.70 (+2.10), KITE: 60.61 (+2.94), CGEN: 8.60 (+0.27), FOLD: 8.61 (+0.29), KPTI: 37.99 (+0.56)
Amarin Corporation: Upside Becomes Clearer While The Path To The Finish Line Remains Murky
Outsized Analytics - at Seeking Alpha - Sun Dec 07, 8:47AM CST
AMRN: 1.13 (+0.15), AZN: 70.40 (+0.02), GSK: 42.37 (-0.37)
Amarin to Present at the 25th Annual Oppenheimer Healthcare Conference
Marketwired - Thu Dec 04, 6:02AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the 25th Annual Oppenheimer Healthcare Conference in New York City on Thursday, December 11, at 3:20 p.m. ET.
AMRN: 1.13 (+0.15)
Amarin: The Silence Of The Lamb
Scrying Biotech - at Seeking Alpha - Tue Dec 02, 9:08AM CST
AMRN: 1.13 (+0.15)
Why Amarin Corporation PLC Stock Flew 37% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 01, 1:27PM CST
AMRN data by YCharts What: Shares of Amarin , a small-cap biopharmaceutical company focused on developing therapies that are designed to treat cardiovascular diseases, rocketed higher by 37% in November, according to data from S&P...
AMRN: 1.13 (+0.15)
5 Under-$10 Stocks Setting Up to Trade Higher: Must-See Charts
at The Street - Mon Dec 01, 11:26AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
SYN: 1.55 (+0.09), AMRN: 1.13 (+0.15), JCP: 6.29 (-0.19), SNSS: 2.75 (+0.20), SWHC: 9.48 (+0.01)
Update: Amarin Earnings Show It Blew Its Chance At 2014 Profitability
The Specialist - at Seeking Alpha - Mon Nov 24, 12:13AM CST
AMRN: 1.13 (+0.15)
Traders Get Bullish on Shares of Amarin, Shares Up 9.7% (AMRN)
Comtex SmarTrend(R) - Fri Nov 21, 12:41PM CST
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 9.7% to $1.36 on 1.1x average daily volume. Amarin has traded 2.3 million shares thus far today, vs. average volume of 2.0 million shares per day. The stock has outperformed the Dow (9.7% to the Dow's 0.3%) and outperformed the S&P 500 (9.7% to the S&P's 0.3%) during today's trading.
AMRN: 1.13 (+0.15)
Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:18AM CST
Amarin Corporation plc (AMRN) was a big mover last session, as the company saw its shares rise by over 23% on the day.
ANIP: 56.99 (+0.60), AMRN: 1.13 (+0.15), AMAG: 42.60 (-0.02), AFFX: 9.99 (+0.12)
Amarin Announces Presentation of MARINE and ANCHOR Analyses at the American Heart Association Scientific Sessions Showing Vascepa(R) Significantly Reduced Remnant-Like Particle Cholesterol in Hypertriglyceridemic Patients
Marketwired - Tue Nov 18, 11:17PM CST
Amarin Corporation Plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa® (icosapent ethyl) capsules significantly reduced remnant-like particle cholesterol (RLP-C) levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride (TG) levels ≥ 200 mg/dL and ≥ 500 mg/dL, including patients that received statin therapy. The data were presented today by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago.
AMRN: 1.13 (+0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 11:49AM CST
BOSC: 3.28 (+0.12), ANV: 0.91 (+0.04), BONE: 3.00 (-0.03), TERP: 30.84 (-0.04), BDR: 2.35 (-0.34), AMRN: 1.13 (+0.15), NBS: 3.73 (-0.04), YOKU: 18.31 (+0.50), AMCF: 1.51 (-0.03), GSAT: 2.68 (-0.07), MUX: 1.10 (-0.01), URBN: 35.10 (-0.03), CANF: 3.77 (+0.27), TRT: 2.74 (-0.17), CBSO: 27.51 (+0.58), OME: 10.60 (+0.03), ATLC: 2.60 (+0.24), SUNE: 19.71 (+0.20), FWM: 3.12 (-0.03)
Amarin up again today on Vascepa data
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 10:41AM CST
AMRN: 1.13 (+0.15)
Amarin Up 5.3%, Shares Break Through Resistance (AMRN)
Comtex SmarTrend(R) - Mon Nov 17, 2:42PM CST
Amarin (NASDAQ:AMRN) is one of today's best performing low-priced stocks, up 5.3% to $1.00 on 1.1x average daily volume. Thus far today, Amarin has traded 1.8 million shares, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.3% to the Dow's 0.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.0%) during today's trading.
AMRN: 1.13 (+0.15)
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
at The Street - Fri Nov 14, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OREX: 6.30 (+0.24), AMRN: 1.13 (+0.15), ICPT: 159.49 (+3.49), SPPI: 7.15 (+0.22), MNKD: 5.64 (+0.42)
Rick Harrison of Television's "Pawn Stars(R)" Takes His Patient-Care Message to AHA Scientific Sessions to Raise Awareness of Very High Triglycerides as Part of National Campaign
Marketwired - Thu Nov 13, 6:04AM CST
Making the right deal can meaningfully impact and improve your health when it comes to speaking with your doctor. Rick Harrison, star of the hit television show, "Pawn Stars®," will attend the American Heart Association's (AHA) Scientific Sessions to raise awareness of very high triglycerides (VHTG) (≥ 500 mg/dL), a condition that affects up to four million Americans.(1) Mr. Harrison's AHA visit is sponsored by Amarin Corporation, plc (NASDAQ: AMRN).
AMRN: 1.13 (+0.15)
Update: Amarin's Q3 2014 Earnings Report
Elephant Analytics - at Seeking Alpha - Mon Nov 10, 12:18AM CST
AMRN: 1.13 (+0.15)
Amarin Reports Third Quarter 2014 Financial Results and Provides Update on Operations
Marketwired - Thu Nov 06, 3:04PM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and nine months ended September 30, 2014, and provided an update on company operations.
AMRN: 1.13 (+0.15)
